A case of type 2B von Willebrand disease reverse to normal when treated with high doses of protease inhibitor.
Arkel
Y S
YS
Ku
D H
DH
Lake
C
C
Pasquale
L
L
Lam
X
X
Gibson
D
D
Burstin
S
S
D019943:Amino Acid Substitution; D001704:Biopolymers; D005260:Female; D006801:Humans; D019888:Nelfinavir / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D017354:Point Mutation; D011182:Postoperative Care; D011300:Preoperative Care; D011480:Protease Inhibitors / Q000627:therapeutic use*; D017434:Protein Structure, Tertiary; D012310:Ristocetin / Q000494:pharmacology; D014842:von Willebrand Diseases / Q000188:drug therapy* / Q000235:genetics; D014841:von Willebrand Factor / Q000737:chemistry / Q000235:genetics
D001704:Biopolymers; D011480:Protease Inhibitors; D014841:von Willebrand Factor; D012310:Ristocetin; D019888:Nelfinavir